3.70Open3.70Pre Close0 Volume88 Open Interest14.00Strike Price0.00Turnover0.00%IV4.92%PremiumDec 20, 2024Expiry Date2.87Intrinsic Value100Multiplier0DDays to Expiry0.83Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.13Leverage Ratio--Theta--Rho--Eff Leverage--Vega
ACADIA Pharmaceuticals Stock Discussion
ACADIA Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
$Infobird Software (IFBD.US)$ Completed $40M acquisition. China stock. Low float. 0 shares LTB✅
$Ocean Power Technologies (OPTT.US)$ Form 4 insider buying. 0 shares LTB✅
$T Stamp (IDAI.US)$ Ran today. Up after hours. Possible catalyst. Low float. 0 shares LTB✅
$Syra Health (SYRA.US)$ Recent Form 4s multiple insider loading. Low fl...
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
Acadia Pharmaceuticals (NASDAQ: ACAD) has secured an exclusive worldwide license agreement with Saniona for SAN711, a first-in-class GABAA-α3 positive allosteric modulator.
The company plans to develop SAN711 for essential tremor treatment, with Phase 2 studies expected to begin in 2026. Under the agreement, Saniona will receive a $28 million upfront payment plus potential ...
ACADIA Pharmaceuticals Inc - Saniona to Receive $28 Million Upfront Plus up to $582 Million in Milestones with exclusive licensing agreement with Saniona for San711
ACADIA Pharmaceuticals Enters Into an Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$